Pfizer’s Meningitis B Vaccine Trumenba Is CBER’s First ‘Breakthrough’ Approval

FDA’s biologics center grants accelerated approval to the first U.S. vaccine targeting serogroup B meningococcal disease after a 4.5-month review; the vaccine is expected to come up for discussion, but not a vote, at CDC’s Advisory Committee on Immunization Practices meeting Oct. 30.